A Study to Assess the Safety, Tolerability and Pharmacokinetics of Viaca (Sildenafil + Cabergoline) Compared With Sildenafil and Cabergoline

Inclusion Criteria: * Male participants, aged 18 to 65 years (inclusive) at the time of informed consent. * In good general health (Investigator judgement) with no significant medical history and no clinically significant abnormalities on physical examination, vital signs, or 12-lead ECG - including systolic blood pressure 110-140 mmHg (inclusive) at Screening and Day -1 - at Screening and/or before first IP administration. * BMI ≥ 18.0 and ≤ 32.0 kg/m² and weight ≥ 50 kg. * Nonsmoker or casual smoker (\< 5 cigarettes/week equivalent) with no tobacco use within 2 months prior to Screening (Investigator discretion). * Clinical laboratory values within normal range (or not clinically significant per Investigator). * Fertile men agree to acceptable contraception from Screening until 90 days after last IP dose, and no sperm donation from first dose until ≥ 90 days after last dose. * Able and willing to attend required study visits. * Able and willing to provide written informed consent before any study procedures. Exclusion Criteria: * Physical or psychological condition that would impair protocol compliance or study completion (Investigator judgement). * History of, or condition that would contraindicate study medication or interfere with study evaluations (Investigator judgement). * Previous history of any of: myocardial infarction; cerebrovascular accident; arrhythmia; congestive heart failure; unstable angina; recent (\<6 months) need for calcium-channel/beta-blocker/nitra…